Good morning, everyone, and welcome to another working week. We hope the weekend respite — or holiday break, for some — was invigorating and refreshing, because the oh-so-familiar routine of meetings, deadlines, conference calls, and the like has, of course, returned. But what can you do? The world keeps spinning, no matter what. So on that note, please join us for a needed cup or three of stimulation — we fancy butter pecan today, if suggestions are needed — and enjoy the menu of tidbits assembled for you. Hope you have a smashing day and, as always, please do keep in touch …

An unnamed Novartis (NVS) executive sold $946,000 worth of shares less than three weeks before the Food and Drug Administration announced data from tests of its Zolgensma gene therapy were manipulated, Reuters writes. The stock sale by an executive member of the board or executive committee was disclosed in a July 19 Swiss stock exchange filing. Novartis says “the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy